(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 7.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Ionis Pharmaceuticals's revenue in 2025 is $944,051,000.On average, 9 Wall Street analysts forecast IONS's revenue for 2025 to be $136,666,183,917, with the lowest IONS revenue forecast at $132,737,827,687, and the highest IONS revenue forecast at $151,804,206,500. On average, 9 Wall Street analysts forecast IONS's revenue for 2026 to be $133,785,506,235, with the lowest IONS revenue forecast at $108,629,904,300, and the highest IONS revenue forecast at $160,347,576,374.
In 2027, IONS is forecast to generate $197,633,647,792 in revenue, with the lowest revenue forecast at $145,360,019,111 and the highest revenue forecast at $228,726,413,615.